EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

Anders Juul iD, Philippe Backeljauw, Michael Højby, Masanobu Kawai iD, Rasmus Juul Kildemoes, Agnès Linglart iD, Nehama Zuckerman-Levin, Reiko Horikawa iD

European Journal of Endocrinology · 2023

DOI: 10.1093/ejendo/lvac008 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Anders Juul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Body Height, Human Growth Hormone, Infant, Small for Gestational Age. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Investigate efficacy, safety, and tolerability of 3 once-weekly somapacitan doses compared with daily growth hormone (GH) administration in short children born small for gestational age (SGA).

Design

Randomised, multi-centre, open-label, controlled phase 2 study comprising a 26-week main phase and a 4-year extension (NCT03878446). The study was conducted at 38 sites across 12 countries. 26-week main phase results are presented here. Sixty-two GH treatment-naïve, prepubertal short children born SGA were randomised and exposed; 61 completed the main phase. Three somapacitan doses (0.16 [n = 12], 0.20 [n = 13], 0.24 [n = 12] mg/kg/week) and 2 daily GH doses (0.035 [n = 12], 0.067 [n = 13] mg/kg/day) were administered subcutaneously.

Results

After 26 weeks of treatment, the estimated mean annualised height velocity (HV) was 8.9, 11.0, and 11.3 cm/year for somapacitan 0.16, 0.20, and 0.24 mg/kg/week, respectively, compared to 10.3 and 11.9 cm/year for daily GH 0.035 and 0.067 mg/kg/day. Changes from baseline in HV standard deviation score (SDS), height SDS, and insulin-like growth factor I (IGF-I) SDS showed similar dose-dependent responses. Exposure-response modelling indicated the greatest efficacy correlated with the highest somapacitan exposure. Similar safety and tolerability were demonstrated for all weekly somapacitan and daily GH doses.

Conclusions

Based on the totality of data on improvements in height-based parameters combined with exposure-response analyses, somapacitan 0.24 mg/kg/week appears most efficacious, providing similar efficacy, safety, and tolerability as daily GH 0.067 mg/kg/day in short children born SGA after 26 weeks of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body HeightHuman Growth HormoneInfant, Small for Gestational AgeChildFemaleHumansInfant, NewbornGestational AgeInsulin-Like Growth Factor IHistidineMannitolPhenol

Stichwörter der Autor:innen

growth hormonelong-acting growth hormonesmall for gestational agesomapacitan

Substanzen

Human Growth HormoneInsulin-Like Growth Factor IsomapacitanHistidineMannitolPhenol

Autor:innen und Institutionen

  • Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen 2200, Denmark.
  • Division of Endocrinology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States.
  • Clinical Drug Development, Novo Nordisk A/S, Søborg 2860, Denmark.
  • Department of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka 594-1101, Japan.
  • AP-HP, Université Paris Saclay, INSERM, Service d'Endocrinologie et Diabète de l'Enfant, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre 94270, France.

ORCID-Profile: Anders Juul, Masanobu Kawai, Agnès Linglart, Reiko Horikawa

Förderung

  • Novo Nordisk

Zitieren

APA

Juul, A., Backeljauw, P., Højby, M., Kawai, M., Kildemoes, R. J., Linglart, A., Zuckerman-Levin, N., & Horikawa, R. (2023). Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvac008

Vancouver

Juul A, Backeljauw P, Højby M, Kawai M, Kildemoes RJ, Linglart A, et al. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvac008

BibTeX
@article{Juul2023,
  author = {Juul, Anders and Backeljauw, Philippe and Højby, Michael and Kawai, Masanobu and Kildemoes, Rasmus Juul and Linglart, Agnès and Zuckerman-Levin, Nehama and Horikawa, Reiko},
  title = {Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study},
  journal = {European Journal of Endocrinology},
  year = {2023},
  doi = {10.1093/ejendo/lvac008}
}
Kostenlos starten →